Product Overview

IVFhCG 5000 is a pharmaceutical preparation containing Human Chorionic Gonadotropin (HCG) at a strength of 5000 International Units per vial. Manufactured by Neova Biogene Private Limited, this product is supplied in a sterile 1 ml vial designed for intramuscular or subcutaneous administration. The medication is indicated for the treatment of female infertility associated with anovulation or inadequate endogenous gonadotropin secretion, as well as for male hypogonadism resulting from deficient endogenous gonadotropins. Each package offers flexible pack sizes of 3, 6, or 9 vials, providing a convenient option for patients undergoing assisted reproductive technologies or hormone replacement protocols. The product complies with regulatory standards set by the Central Drugs Standard Control Organization (CDSCO) and is shipped within 6 to 15 days to most international destinations.

What is IVFhCG 5000

IVFhCG 5000 belongs to the class of gonadotropins, which are glycoprotein hormones that mimic the action of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) in the body. The active ingredient, HCG, is a naturally occurring hormone produced by the placenta during pregnancy. In clinical practice, recombinant or purified HCG is used to stimulate the ovaries in ovulation induction, support luteal phase function, and restore endogenous testosterone production in men with hypogonadism. The 5000 IU dosage is a standard strength for fertility applications, offering a balance between efficacy and tolerability. For detailed scientific background, refer to the National Institutes of Health’s resource on Human Chorionic Gonadotropin.

Uses and Benefits

The primary uses of IVFhCG 5000 are centered on reproductive endocrinology and endocrine therapy. In women, it is employed to trigger final follicular maturation and ovulation in controlled ovarian stimulation cycles, thereby increasing the probability of successful fertilization and embryo implantation. Clinical studies have demonstrated that HCG administration can improve pregnancy rates when combined with assisted reproductive techniques such as in‑vitro fertilization (IVF) and intrauterine insemination (IUI). In men, HCG therapy helps to restore endogenous testosterone production by stimulating Leydig cells in the testes, which can alleviate symptoms of hypogonadism such as low libido, fatigue, and reduced muscle mass. Additional benefits include the potential to improve sperm count and quality in select patient populations. The medication is also valued for its predictable pharmacokinetics, ease of dosing, and compatibility with other hormonal agents used in fertility regimens.

How It Works

IVFhCG 5000 functions by binding to the LH/FSH receptors on ovarian granulosa cells and testicular Leydig cells, thereby activating intracellular signaling pathways that promote steroidogenesis. In the ovary, this results in the final maturation of the dominant follicle and the release of the oocyte, a process that is timed to coincide with the optimal window for sperm availability or embryo transfer. In the testes, HCG stimulation leads to increased production of testosterone, which in turn supports spermatogenesis and secondary sexual characteristics. The hormonal cascade initiated by HCG mirrors the natural luteinizing hormone surge that occurs mid‑cycle, ensuring physiological relevance and minimizing the risk of receptor desensitization. For a comprehensive explanation of gonadotropin mechanisms, consult the U.S. Food and Drug Administration guidance on fertility drugs.

Dosage Guidelines

Dosage of IVFhCG 5000 is individualized based on the patient’s clinical condition, response to prior therapy, and the specific protocol employed by the treating physician. For ovulation induction in women, a typical regimen involves a single intramuscular injection of 5000 IU administered when follicular size reaches a pre‑determined threshold (commonly 18–20 mm). In some protocols, a split dose of 2500 IU followed by a second dose of 2500 IU may be used to enhance follicular development. For male hypogonadism, the recommended dose is often 5000 IU administered intramuscularly every 7–10 days for a defined treatment cycle, with adjustments made based on serum testosterone levels. Patients are advised to follow the dosing schedule provided by their healthcare provider and to avoid self‑adjusting the dose without medical supervision. Proper storage at 2‑8 °C protects the biologics from degradation, and the vial should be inspected for particulate matter before each use.

Side Effects

Like all biologics, IVFhCG 5000 may be associated with adverse effects, most of which are mild and transient. Common side effects include injection site reactions such as redness, swelling, or bruising, as well as mild abdominal discomfort. Systemic reactions can comprise headache, nausea, and fatigue. Less frequently, patients may experience ovarian hyperstimulation syndrome (OHSS) in women, characterized by abdominal distension, rapid weight gain, and shortness of breath; prompt medical evaluation is recommended if these symptoms arise. Allergic responses, though rare, can manifest as rash, pruritus, or urticaria and may require discontinuation of therapy. Patients should report any persistent or severe symptoms to their physician without delay. For a thorough review of HCG safety data, refer to the MedlinePlus entry on Human Chorionic Gonadotropin.

Warnings and Precautions

IVFhCG 5000 should be used only under the supervision of a qualified healthcare professional. Contraindications include known hypersensitivity to HCG or any of the excipients, as well as active or suspected hormone‑sensitive cancers. Caution is advised in patients with a history of thromboembolic disorders, cardiovascular disease, or severe renal impairment, as hormonal fluctuations can exacerbate these conditions. Pregnant women should not receive HCG therapy unless specifically indicated for medical reasons, and breastfeeding individuals must discuss potential risks with their clinician. Regular laboratory monitoring, including serum hormone levels and ultrasound assessments, is essential to evaluate treatment response and to mitigate complications. Proper documentation of the medication’s lot number and expiration date is required to ensure product integrity throughout the treatment course.

FAQs

1. Question: What is the difference between IVFhCG 5000 and lower‑strength HCG preparations?
   Answer: The primary distinction lies in the dosage strength; IVFhCG 5000 delivers 5000 International Units per vial, which is commonly used for ovulation triggering and testosterone stimulation, whereas lower‑strength preparations (e.g., 1000 IU) are often employed for maintenance therapy or specific step‑up protocols.
2. Question: How should IVFhCG 5000 be stored before use?
   Answer: The vials must be refrigerated at 2 °C–8 °C and protected from light. Once reconstituted, the solution can be kept at room temperature for up to 24 hours, but it should not be frozen.
3. Question: Can IVFhCG 5000 be used in combination with other fertility drugs?
   Answer: Yes, it is frequently combined with gonadotropins such as FSH or with aromatase inhibitors in controlled ovarian stimulation regimens; however, the exact combination and timing should be determined by a reproductive endocrinologist.
4. Question: Is IVFhCG 5000 safe for patients with polycystic ovary syndrome (PCOS)?
   Answer: In PCOS patients, HCG may be used cautiously to induce ovulation, but clinicians must monitor for an exaggerated response and adjust dosing to reduce the risk of OHSS.
5. Question: What is the typical delivery time for IVFhCG 5000 after ordering?
   Answer: Orders are typically processed within 6 to 15 days, depending on the destination and customs clearance procedures.